Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A

Shanxi C&Y Pharmaceutical Group Co., Ltd. Class A

SSZSE:300254
7.05
CNY
-0.19
(-2.62%)
0.15EPS
100.39P/E
2.36BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.66
4.07
4.15
3.46
4.49
5.46
5.43
3.98
4.08
3.5
3.31
3.5
3.59
3.27
Basic EPS, GAAP
0.14
0.26
0.14
0.14
0.1
0.03
0.03
-1.23
-0.4
-0.5
0.1
0.17
0.1
0.09
Free Cash Flow per Basic Share
0.12
0.3
-0.12
-0.04
-0.29
0.04
0.25
-0.25
0.26
0.2
0.02
0.08
0.26
- -
Dividend per Share
0.09
0.12
0.14
0.1
0.12
0.12
0.09
0.1
0.06
0.05
0.06
0.05
0.08
0.07
Book Value per Share
3.17
3.31
3.77
3.88
3.93
3.91
3.92
3.01
2.59
2.38
2.48
1.38
1.19
1.95
Tangible Book Value per Share
1.8
1.62
2.25
2.14
2.33
2.52
2.66
0.3
0.06
0.13
0.31
-0.71
-0.83
-0.04
Basic Weighted Avg Shares
193
161
165
215
209
208
209
213
228
237
242
242
243
244
Sales/Revenue/Turnover
514
654
684
746
939
1,136
1,132
848
930
829
799
847
871
798
Operating Margin (%)
8.76
8.53
7.81
6.26
4.92
4.48
-0.58
-20.98
-1.24
-2.19
4.2
9.67
13.25
10.8
Depreciation Expense
26
37
43
48
50
56
52
65
67
65
59
58
59
- -
Net Income, GAAP
27
41
23
30
22
7
5
-262
-91
-119
25
42
25
22
Effective Tax Rate (%)
17.93
7.18
24.23
15.14
25.15
33.87
193.82
- -
- -
- -
11.85
7.3
37.84
36.87
Profit Margin (%)
5.28
6.27
3.35
4.04
2.31
0.64
0.47
-30.94
-9.83
-14.3
3.15
4.98
2.85
2.8
Working Capital
123
138
228
205
127
236
257
87
-24
-92
-16
-70
-13
14
LT Debt
90
70
130
100
30
128
190
113
39
196
159
184
239
269
Total Equity
767
823
872
955
971
947
933
873
745
730
778
598
594
561
Return on Invested Capital (%)
4.09
5.04
2.28
1.79
1.77
-0.79
3.07
- -
- -
- -
2.87
5.5
4.54
- -
Return on Capital (%)
2.75
3.45
2.36
3.08
1.99
1.12
-0.37
- -
- -
- -
2.47
2.27
0.61
- -
Return on Common Equity (%)
4.5
6.57
3.22
3.78
2.66
0.89
0.65
-34.91
-14.33
-20.36
4.29
8.95
7.67
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
296
241
244
LT Borrowings
258
254
253
LT Finance Leases
17
16
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
256
256
257
Market Capitalization
2,888
2,051
2,364

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
564
518
559
Cash, Cash Equivalents & STI
138
97
134
Accounts Receivable, Net
184
168
163
Inventories
149
173
159
Total Current Liabilities
572
520
544
Payables & Accruals
- -
- -
- -
ST Debt
296
241
244
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.31%
-6.76%
-0.64%
Free Cash Flow
96.67%
58.72%
221.25%
Net Income, GAAP
-527.37%
-26.09%
-41.1%
Sales/Revenue/Turnover
3.45%
0.8%
2.86%
Total Cash Common Dividend
0.56%
1.99%
53.94%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
189
212
208
238
847
2025
182
191
- -
259
871
2026
174
178
186
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.06
0.04
-0.01
0.17
2025
0.04
-0.04
- -
0.01
0.1
2026
0.01
- -
0.06
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.05
2025
0.02
0.02
- -
0.02
0.08
2026
0.02
0.02
0.02
- -
- -

Company Description

CEO
Qun Zhao
Full Time Employees
1,162
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Room 3605-3610 Datong SX China 200232
IPO Date
Aug 5, 2011
Business
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ) is a pharmaceutical company engaged in the research, development, production, and sale of medicines, health foods, and related medical services. The company offers a diverse portfolio of products including anti-infective drugs; anti-allergic drugs such as Ebastine tablets; respiratory system drugs like Ambroxol hydrochloride dispersible tablets and Montmorillonite powder; urinary system drugs including Tamsulosin hydrochloride sustained release capsules; kidney disease drugs such as Cinacalcet hydrochloride tablets; children's medicines like Vitamin AD drops; cardiovascular and cerebrovascular drugs; antidepressants including Fluoxetine hydrochloride capsules; smoking cessation drugs such as Varenicline tartrate tablets; pharmaceutical raw materials and intermediates; and Baoling Jingbao oral liquid. It also provides medical and health services encompassing medical diagnosis, gene preservation, pregnancy environment testing, and clinical laboratory services through subsidiaries. Founded in 2005 as Shanxi Qianyuan Pharmaceutical Co., Ltd., the company, headquartered in Shanghai, China, listed on the Shenzhen Stock Exchange GEM in August 2011 and changed its name to ShanXi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Operations span multiple segments including medicine, health food, and services, with geographic revenue primarily from East China, Central China, North China, South China, Southwest China, Northwest China, and Northeast China, alongside minor overseas sales. The company maintains production bases and subsidiaries such as Hangzhou Baoling Pharmaceutical, Zhejiang Hailisheng Pharmaceutical, Jiangsu Jiayi Pharmaceutical, Hangzhou Ens hi Gene, Sichuan Qianyuan Traditional Chinese Medicine, Wuxi Lianhe Likang Clinical Laboratory, and Tibet Qianyuan, supporting its focus on chemical synthesis drugs, biological drugs, natural drugs, APIs, intermediates, traditional Chinese medicines, and healthcare products. In recent years, ShanXi C&Y Pharmaceutical Group has pursued strategic expansions, including the 2016 acquisition of Wuxi Lianhe Likang Clinical Laboratory Co., Ltd. to bolster its medical testing capabilities, and a 2020 strategic shift to emphasize high-end pharmaceuticals as the core business with precision medicine and health foods as key wings. The company continues to optimize its product structure through mergers, investments, and R&D enhancements via its advanced drug research institute, while extending services across 34 provincial administrative regions in China and into international markets. As of 2025, it employs over 1,600 people and reports ongoing involvement in innovative drug developments amid industry trends like commercial insurance payments and overseas authorizations.